Skip to main content
Mary Vance, MD, Endocrinology, Charlottesville, VA

MaryL.VanceMD

Endocrinology • Charlottesville, VA

Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology

Professor of Medicine, University VA School of Medicine

Join to view full profile

Dr. Vance is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Vance's full profile

Already have an account?

  • Office

    415 Ray C Hunt Dr
    Ste 2100
    Charlottesville, VA 22903
    Phone+1 434-982-3591
    Fax+1 434-924-5894

Education & Training

  • University of Virginia Medical Center
    University of Virginia Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1980 - 1983
  • Baylor University Medical Center
    Baylor University Medical CenterResidency, Internal Medicine, 1977 - 1980
  • Louisiana State University School of Medicine in New Orleans
    Louisiana State University School of Medicine in New OrleansClass of 1977

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 1981 - 2026
  • TX State Medical License
    TX State Medical License 1977 - 1993
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Pathology of Prolactinomas: Any Predictive Value?
    Pathology of Prolactinomas: Any Predictive Value?October 22nd, 2019

Grant Support

  • Preoperative Bexarotene Treatment For Cushing'S DiseaseNational Center For Research Resources2010
  • Clinical Trial: Effect Of Growth Hormone Treatment On Recovery From Cushing'S DINational Center For Research Resources2008–2010
  • Effect Of Growth Hormone Treatment On Recovery From Cushing'S DiseaseNational Center For Research Resources2005–2007
  • The Efficacy And Safety;Pegvisomant Vsasandostatin LARNational Center For Research Resources2006
  • Pegvisomant;Sandostatin Lar;Pegvisomant PLUS Sandostatin LAR In AcromegalyNational Center For Research Resources2005–2006
  • The Efficacy And Safety;Pegvisomant VS Sandostatin LARNational Center For Research Resources2005
  • Surgical Debulking;Response To Octreotide LAR, AcromegalyNational Center For Research Resources2005
  • Pegvisomant And Sandostatin LAR In AcromegalyNational Center For Research Resources2004
  • Efficacy And Safety;Pegvisomant VS Sandostatin LARNational Center For Research Resources2004
  • Metabolic Effects Of Growth Hormone In GH Deficient AdulNational Center For Research Resources2000–2002
  • B2036-PEG In Treatment Of AcromegalyNational Center For Research Resources2000–2002
  • 24 HR Urinary Free Cortisol Excretion In Reponse To Dexamethasone In African AmerNational Center For Research Resources2000–2002
  • Sandostatin LARNational Center For Research Resources1999–2002
  • Double Blind, Placebo Controlled Trial Of B2036 PEG In AcromegalyNational Center For Research Resources1999–2002
  • OPEN Label Trial Of B2036 PEG In Treatment Of AcromegalyNational Center For Research Resources1998–2002
  • Lanreotide In AcromegalyNational Center For Research Resources1998–2002
  • B2036 PEG In The Treatment Of AcromegalyNational Center For Research Resources1998–1999
  • 24-Hr Urinary Free Cortisol Excretion &Dexamethasone Response In WomenNational Center For Research Resources1996–1999
  • OPEN Label Pharmokinetic Study Of Prolease Hgh In GH Deficient AdultsNational Center For Research Resources1997
  • Oral Dose Regimen Finding Study Of Gpa-748 In GH Deficient AdultsNational Center For Research Resources1996–1997
  • Cabergoline In The Treatment Of Prolactin Secreting Pituitary MacroadenomaNational Center For Research Resources1992–1997
  • Continuous, Pulsatile, And Single Dose GH Administration In Gh-Deficient AdultsNational Center For Research Resources1995–1996
  • Subcutaneous Synthetic Growth Hormone Response Study In Normal ManNational Center For Research Resources1994–1996
  • Study Of Nutropin In Treatment Of Growth Hormone Deficient AdultsNational Center For Research Resources1994–1996
  • Multicenter Study To Define Safety And Efficacy Of Chronic SandostatinNational Center For Research Resources1995
  • Safety Of Chronic Sandostatin Treatment In Acromegalic PatientsNational Center For Research Resources1993–1994
  • Sandostatin On GH Secretion And Carbohydrate Lipid And Protein MetabolismNational Center For Research Resources1992
  • Dose Ranging Study Of Cgs-15873a In Hypeprolactinemic PatientsNational Center For Research Resources1992
  • Subcutaneous Synthetic GH Dose Response Study In Normal ManNational Center For Research Resources1991–1992
  • Safety And Efficacy Of Chronic Sandostatin Treatment In Acromegalic PatientsNational Center For Research Resources1990–1992
  • Physiologic GH Replacement--Protein, Lipid And Carbohydrate MetabolismNational Center For Research Resources1990–1992
  • Growth Hormone Secretion In Burn InjuryNational Center For Research Resources1990–1992
  • Efficacy Of CV 205-502 In Patients With HyperprolactinemiaNational Center For Research Resources1989–1992
  • GH Suppression--Effect On Proliferative Diabetic RetinopathyNational Center For Research Resources1991
  • Sandostatin In The Treatment Of AcromegalyNational Center For Research Resources1990–1991
  • Progesterone Therapy On Gonadotropin Secreting Psychological Symptoms In PMSNational Center For Research Resources1990
  • Humatrope Effects On Growth Hormone Binding ProteinNational Center For Research Resources1990
  • Efficacy, Systemic Tolerance And Topical Safety Of Transdermal TestosteroneNational Center For Research Resources1989–1990
  • Diagnosis And Treatment Of Carcinoid Tumors With I-131 MetaiodobenzylguanidineNational Center For Research Resources1989–1990
  • Investigation Of CV 201-502 In The Treatment Of Hyperprolactinemic WomenNational Center For Research Resources1987–1990
  • Efficacy, Systemic Tolerance, Topical Safety Of Transdermal TestosteroneNational Center For Research Resources1987–1989
  • Determination Of The Serum Half Life Of Endogenous GH In Normal MenNational Center For Research Resources1987–1989
  • Determination Of Clinical Effects And Dose Response Relationships Of GHNational Center For Research Resources1987–1989
  • Progesterone Therapy On Gonadotropin Secreting Psychological SymptomsNational Center For Research Resources1987
  • Progesterone Therapy In Premenstrual SyndromeNational Center For Research Resources1986
  • Efficacy Of Testosterone Therapy In HypogonadismNational Center For Research Resources1986
  • Testolactone Effect On Gonadotropin RegulationEunice Kennedy Shriver National Institute Of Child Health &Human Development1985

Dr. Mary Vance, Dr. Mary Vance, MD, Dr. M Vance, Dr. Mary L. Vance